User:Billlarddd/sandbox

Nolan Williams, M.D.

Background
Nolan Williams, M.D., is a prominent psychiatrist and neuroscientist known for his innovative work in the field of brain stimulation therapies. He serves as Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. Dr. Williams is recognized for his groundbreaking work in developing innovative technologies and therapeutics aimed at modulating neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions.

Education
Dr. Williams completed his undergraduate studies with a B.S. in Biology from the College of Charleston, Charleston, South Carolina, in 2003. He earned his M.D. from the Medical University of South Carolina, Charleston, SC 2008. His post-graduate training includes an internship in Internal Medicine at the The Medical University of South Carolina (2008-2009), residency training in Neurology and Psychiatry at the same institution (2009-2014), an Interventional Psychiatry Fellowship (2012-2014), and an R25 Human Neuroscience Fellowship (2012-2014), both mentored by Mark George, MD, at the Medical University of South Carolina.

Career
Dr. Williams began his academic career at Stanford University, progressing to his current role as Associate Professor. As the Director of the Stanford Brain Stimulation Lab, he leads a team dedicated to developing neuroimaging-based approaches to target therapeutic delivery and predict treatment responses to neuromodulation and psychedelics. His clinical expertise includes developing and implementing novel therapeutics for central nervous system illnesses.

Research and Contributions
Dr. Williams' research focuses on advanced neuromodulation techniques and psychedelic therapies. Over the past decade, his laboratory has pioneered several groundbreaking therapeutic approaches. One of his most significant achievements is the development of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a rapid-acting, non-invasive neuromodulation therapy for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status in 2021 and FDA Clearance in 2022. It is also the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP ). As of April 2024, SAINT has been reimbursed for patients with severe depression in inpatient psychiatric units, and the technology is being deployed worldwide in both clinical and research settings. ​

Dr. Williams is also an expert in psychedelic medicines for neuropsychiatric illnesses. He is the first investigator to conduct mechanistic clinical trials on the neurobiological effects of ibogaine, a powerful psychedelic compound with potential therapeutic benefits. His research with ibogaine has shown promising results in reducing PTSD, anxiety, and depression symptoms in veterans with traumatic brain injury​.

In 2018, Dr. Nolan Williams cofounded a medical technology company called Magnus Medical. The organization is at the forefront of developing advanced neuromodulation devices to revolutionize the treatment of psychiatric and neurological disorders. Magnus Medical's mission is to harness cutting-edge neuroscience and engineering to create effective, non-invasive therapeutic solutions.

In 2021, Dr. Williams founded the Psychedelics and Consciousness Lab at Stanford University. This lab focuses on exploring the therapeutic potential of psychedelics in treating various mental health conditions.

Appointments and Positions
Dr. Williams held the position of Chief Resident for both the Neuropsychiatry Residency (2011-2014) and the General Neurology Residency (2011-2012) at the Medical University of South Carolina. At Stanford University, he has served as an Instructor in the Department of Psychiatry from 2014 to 2018, an Assistant Professor from 2019 to 2022, and currently serves as an Associate Professor since 2022. He has been the [https://med.stanford.edu/bsl/about/principalinvestigator.html#:~:text=Nolan%20Williams%2C%20M.D.%20is%20an,the%20Stanford%20Brain%20Stimulation%20Lab. Director of the Stanford Brain Stimulation Laboratory] since 2015 and the Director of the Stanford Interventional Psychiatry Clinical Research Program since 2019. From 2020 to 2022, he also served as the Director of the Koret Human Neuroscience Lab at the Wu Tsai Neuroscience Institute. Additionally, Dr. Williams is a member of the Stanford Neuroscience Institute (since 2017) and Stanford Bio-X (since 2019). He has held leadership roles within the Clinical TMS Society, including Chair of the Clinical Standards Committee (2021-2022) and Director on the Board of Directors (since 2021).

Board Certifications
Dr. Williams is board-certified in Psychiatry by the American Board of Psychiatry and Neurology (2014), Neurology by the American Board of Psychiatry and Neurology (2019), Behavioral Neurology by the United Council for Neurologic Subspecialties (2020), and Neuropsychiatry by the United Council for Neurologic Subspecialties (2020).

Licensure
He holds medical licenses from the South Carolina State Board of Medical Examiners (since May 2010), the Georgia State Board of Medical Examiners (since March 2011), and the California Board of Medical Examiners (since June 2014).

Professional and Scientific Societies Memberships
Dr. Williams is an active member of several professional and scientific societies, including the American Neuropsychiatric Association (since 2007), the American Academy of Neurology (since 2010), the American Psychiatric Association (since 2010), the International Society for ECT and Neurostimulation (since 2012), the North American Neuromodulation Society (since 2012), Biological Psychiatry (since 2012), Human Brain Mapping (since 2016), the Clinical TMS Society (since 2021), and the American College of Neuropsychopharmacology (since 2024).

Committee Memberships
He has served on numerous committees, including the Psychiatry Resident Selection Committee at MUSC (2010-2013), the Neurology Resident Selection Committee at MUSC (2011-2012), the Neurology Strategic Planning Committee at MUSC (2012-2013), the Psychiatry Resident Selection Committee at Stanford (2015-2020), the Committee for Research for the American Neuropsych. Assoc. (2015-2022), the NNDC Opioid Steering Committee (2018-2019), the Scientific Advisory Committee for the Bipolar Roadmap Initiative (2020-2021), and the Clinical Standards Committee for the Clinical TMS Society (2021-2022).

Peer Reviewer
Dr. Williams is a peer reviewer for several grants and manuscripts. His grant review roles include the Research Foundation Flanders (since 2017), PCORI Grant Merit Reviewer (since 2021), Swiss National Science Foundation (since 2021), Milken Institute - Bipolar Disorder Funding Initiative Grant Reviewer (since 2021), FFOR Grant Reviewer (since 2021), and NIH Grant Reviewer (since 2022). He also reviews manuscripts for journals such as the Journal of Neurology, Neurosurgery, and Psychiatry (since 2014), Journal of Neuropsychiatry and Clinical Neurosciences (since 2015), Neuropsychopharmacology (since 2016), Neurocase (since 2016), Human Brain Mapping (since 2017), Brain Stimulation (since 2017), Journal of Academic Psychiatry (since 2017), American Journal of Psychiatry (since 2018), The Lancet Psychiatry (since 2018), Journal of Neurotrauma (since 2018), Cortex (since 2018), Cerebral Cortex (since 2018), Science Advances (since 2019), Journal of Clinical Investigation (since 2019), Biological Psychiatry (since 2019), Nature Medicine (since 2020), Nature Microgravity (since 2020), Cognition (since 2020), Journal of Psychiatric Research (since 2020), Journal of Affective Disorders (since 2020), Proceedings of the National Academy of Sciences (since 2020), Nature Human Behavior (since 2021), and Nature Neuroscience (since 2022).

Honors and Awards
Dr. Williams has received numerous academic and research awards, including the Legislative Incentive for Future Excellence Scholarship, South Carolina (2000-2003), Merit Scholarship from the College of Charleston Honors Program (2000-2003), Rich Scholarship for MD Candidates at the Medical University of South Carolina (2004-2005), NIH R25 Resident Research Training Program for Physician-Scientists (2012-2014), NIH R25 Career Development Institute for Psychiatry (2013-2015), and the NIH Loan Repayment Program (2013-2022). He was honored with the American Neuropsychiatric Association Young Investigator Award (2014), the Society of Biological Psychiatry’s Chairman’s Choice Award (2014), the BBRF Research Partners Program P&S Fund Investigator award (2016-2018), the Society of Biological Psychiatry Domestic Travel Fellowship Award (2018), the American College of Neuropsychopharmacology Travel Fellowship Award (2018), the Chairman’s Award for Advancing Science (2019), the BBRF Klerman Award (2019), the NIMH Biobehavioral Research Award for Innovative New Scientists (2020), the One Mind Bipolar Research Award (2020), the NIH Commercializing Innovation (C3i) Program (2020), and the Leading Research Achievements award from the Brain & Behavior Research Foundation (2020). He also received the BBRF Klerman Award Honorable Mention (2021), the Stanford Department of Psychiatry Chairman’s Award for Clinical Innovation (2022), and the Veterans Exploring Treatment Solution Torchbearer Award (2023), A.E. Bennett Award, Society of Biological Psychiatry (2024).

In recognition of his publications, Dr. Williams received the First Place SC Psychiatric Association Resident Poster Competition award (2011), the American Academy of Neurology Annual Meeting Resident Scholarship (2012), the American Neuropsychiatric Association Trainee Travel Scholarship (2012), the APA Research Colloquium for Junior Investigators award (2013), the MUSC Neurology Resident Teacher of the Year award (2014), the MUSC Psychiatry J.J. Cleckley Clinical Excellence Award (2014), and was recognized for having the #2 Most Talked About Article for American Journal of Psychiatry in both 2018 and 2021, and the #4 Most Talked About Article in 2020.

Published Work
Dr. Williams has published 66 articles in peer-reviewed journals. Some of his notable publications include "Relapse rates with long-term antidepressant drug therapy: a meta-analysis" in Human Psychopharmacology: Clinical and Experimental (2009 ), "Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency" in the Journal of Child Neurology (2010), "High school coaches’ perceptions of physicians’ role in the assessment and management of sports-related concussive injury" in Frontiers in Neurology (2012) , "Unique Case of 'Post-Lumbar Puncture Headache'" in Headache: The Journal of Head and Face Pain (2013) , and "Incidence of sport-related traumatic brain injury and risk factors of severity: a population-based epidemiologic study" in Annals of Epidemiology (2013).

Patents
Dr. Williams holds several patents related to neuromodulation and clinical neuronavigation, including "Systems and methods for predicting and treating neurological condition relapses" (US Patent No. 11992298), and "Systems and methods for personalized clinical applications of accelerated theta-burst stimulation" (US Patent No. 20200214581), and "Systems and methods for clinical neuronavigation" (US Patent No. 11213215).

Professional Appointments  and Positions
Dr. Williams is actively involved in several professional organizations and regularly presents his research at national and international conferences. He also serves on the editorial boards of several scientific journals. His administrative appointments include:


 * Chief Resident for Neuropsychiatry Residency (2011- 2014)
 * Chief Resident for General Neurology Residency (2011-2012)
 * Instructor of Stanford University School of Medicine Department of Psychiatry (2014-2018)
 * Director of Stanford Brain Stimulation Laboratory (2015-present)
 * Member of Stanford Neuroscience Institute (2017-present)
 * Member of Stanford Bio-X (2019-present)
 * Assistant Professor of Stanford University School of Medicine Department of Psychiatry (2019-2022)
 * Director of Stanford Interventional Psychiatry Clinical Research Program (2019-present)
 * Director of Wu Tsai Neuroscience Institute Koret Human Neuroscience Lab (2020-2022)
 * Chair of Clinical TMS Society and Clinical Standards Committee (2021-2022)
 * Director of Clinical TMS Society Board of Director